These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 30925517)

  • 1. Hyperuricaemia and vascular risk: the debate continues.
    Landolfo M; Borghi C
    Curr Opin Cardiol; 2019 Jul; 34(4):399-405. PubMed ID: 30925517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uric acid lowering therapy in cardiovascular diseases.
    Volterrani M; Iellamo F; Sposato B; Romeo F
    Int J Cardiol; 2016 Jun; 213():20-2. PubMed ID: 26386814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of anti-inflammatory therapies, xanthine oxidase inhibitors and other urate-lowering therapies on cardiovascular diseases in gout.
    Richette P; Frazier A; Bardin T
    Curr Opin Rheumatol; 2015 Mar; 27(2):170-4. PubMed ID: 25594854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperuricemia: a novel old disorder-relationship and potential mechanisms in heart failure.
    Borghi C; Palazzuoli A; Landolfo M; Cosentino E
    Heart Fail Rev; 2020 Jan; 25(1):43-51. PubMed ID: 31745840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Gout and cardiovascular risk].
    Němec P
    Vnitr Lek; 2014 Oct; 60(10):893-901. PubMed ID: 25382012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum uric acid and the risk of cardiovascular and renal disease.
    Borghi C; Rosei EA; Bardin T; Dawson J; Dominiczak A; Kielstein JT; Manolis AJ; Perez-Ruiz F; Mancia G
    J Hypertens; 2015 Sep; 33(9):1729-41; discussion 1741. PubMed ID: 26136207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effect of Xanthine Oxidase Inhibitors on Blood Pressure and Renal Function.
    Bove M; Cicero AFG; Borghi C
    Curr Hypertens Rep; 2017 Oct; 19(12):95. PubMed ID: 29071435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An evidence-based review on urate-lowering treatments: implications for optimal treatment of chronic hyperuricemia.
    Bove M; Cicero AF; Veronesi M; Borghi C
    Vasc Health Risk Manag; 2017; 13():23-28. PubMed ID: 28223818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperuricemia and Cardiovascular Disease.
    Zhang S; Wang Y; Cheng J; Huangfu N; Zhao R; Xu Z; Zhang F; Zheng W; Zhang D
    Curr Pharm Des; 2019; 25(6):700-709. PubMed ID: 30961478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Xanthine Oxidase and its Role as Target in Cardiovascular Disease: Cardiovascular Protection by Enzyme Inhibition?
    Schuchardt M; Herrmann J; Tolle M; van der Giet M
    Curr Pharm Des; 2017; 23(23):3391-3404. PubMed ID: 28413972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: a cohort study.
    Kim SC; Schneeweiss S; Choudhry N; Liu J; Glynn RJ; Solomon DH
    Am J Med; 2015 Jun; 128(6):653.e7-653.e16. PubMed ID: 25660249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [URATE AS A POTENTIAL RISK FACTOR OF CARDIOVASCULAR AND RENAL DISEASES].
    Butković M
    Acta Med Croatica; 2016 Dec; 70(4-5):233-9. PubMed ID: 29087102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular and renal effects of hyperuricaemia and gout.
    Viazzi F; Leoncini G; Pontremoli R
    Reumatismo; 2012 Jan; 63(4):253-62. PubMed ID: 22303532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease?
    Dawson J; Walters M
    Br J Clin Pharmacol; 2006 Dec; 62(6):633-44. PubMed ID: 21894646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Febuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout.
    Schumacher HR
    Expert Opin Investig Drugs; 2005 Jul; 14(7):893-903. PubMed ID: 16022578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of urate-lowering therapies on renal handling of uric acid.
    Ma L; Wei L; Chen H; Zhang Z; Yu Q; Ji Z; Jiang L
    Clin Rheumatol; 2016 Jan; 35(1):133-41. PubMed ID: 25373449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic hyperuricemia, uric acid deposit and cardiovascular risk.
    Grassi D; Ferri L; Desideri G; Di Giosia P; Cheli P; Del Pinto R; Properzi G; Ferri C
    Curr Pharm Des; 2013; 19(13):2432-8. PubMed ID: 23173592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allopurinol as a therapeutic option in cardiovascular disease.
    Okafor ON; Farrington K; Gorog DA
    Pharmacol Ther; 2017 Apr; 172():139-150. PubMed ID: 27916655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are serum uric acid levels predictors of cardiovascular risk? An update.
    Georgoulis M; Mikhailidis DP; Panagiotakos DB
    Curr Opin Cardiol; 2023 Jul; 38(4):337-343. PubMed ID: 36789778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular Disease in Gout and the Protective Effect of Treatments Including Urate-Lowering Therapy.
    Gupta MK; Singh JA
    Drugs; 2019 Apr; 79(5):531-541. PubMed ID: 30868398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.